Samsara BioCapital’s Viridian Therapeutics VRDN Stock Holding History

Samsara BioCapital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-60,606	Closed	-$2.75M	–	19
2018 Q4	$2.75M	Buy	+60,606	New	+$3.51M	2.64%	10

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Samsara BioCapital's VRDN Position: Q1 2019 in Review

Samsara BioCapital sold out of Viridian Therapeutics (VRDN) in Q1 2019, closing a stake of 60,606 shares — an estimated $2.75M sold.

Samsara BioCapital first reported a position in VRDN in Q4 2018 and held it in 1 quarter. The position peaked at $2.75M in Q4 2018. 51 funds tracked by Wall St. Rank hold VRDN as of Q1 2019.

Samsara BioCapital reported no remaining Viridian Therapeutics position as of Q1 2019 after selling out during the quarter.
Samsara BioCapital sold 60,606 Viridian Therapeutics shares in Q1 2019, an estimated $2.75M.
Samsara BioCapital first reported a position in Viridian Therapeutics in Q4 2018 and held it in 1 quarter.
Samsara BioCapital's Viridian Therapeutics position peaked at $2.75M in Q4 2018.
51 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2019.

Based on Samsara BioCapital's 13F filing for Q1 2019, filed 15 May 2019.